PapersFlow Research Brief
CNS Lymphoma Diagnosis and Treatment
Research Guide
What is CNS Lymphoma Diagnosis and Treatment?
CNS Lymphoma Diagnosis and Treatment encompasses the clinical evaluation, staging, response assessment, and therapeutic approaches, including chemotherapy regimens like CHOP plus rituximab and methotrexate-based protocols, for primary central nervous system lymphoma (PCNSL), a rare non-Hodgkin lymphoma confined to the brain, spinal cord, or eyes.
The field includes 23,977 works addressing prognostic scoring systems, chemotherapy, radiotherapy, methotrexate, rituximab therapy, genetic features, neurological masquerade syndromes, and cognitive functions in PCNSL patients. Coiffier et al. (2002) demonstrated that adding rituximab to CHOP chemotherapy increased complete-response rates and prolonged event-free and overall survival in elderly patients with diffuse large B-cell lymphoma, a subtype relevant to PCNSL. Cheson et al. (2014) established the Lugano Classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphomas, providing standardized criteria applicable to CNS lymphoma diagnosis.
Topic Hierarchy
Research Sub-Topics
Methotrexate-based Chemotherapy for PCNSL
Researchers optimize high-dose methotrexate regimens, including dosing, delivery, and combination with agents like rituximab. Phase II/III trials assess survival and neurotoxicity outcomes.
Prognostic Scoring Systems in PCNSL
Studies develop and validate models incorporating age, performance status, and genetic markers for risk stratification. Retrospective analyses refine tools like the IELSG score.
Radiotherapy in PCNSL Management
Research evaluates whole-brain radiotherapy timing, dose, and consolidation role post-chemotherapy. Comparative studies balance efficacy against neurocognitive decline risks.
Rituximab Therapy in PCNSL
Investigations test rituximab addition to methotrexate-based protocols in immunocompetent patients. Meta-analyses and randomized trials examine response rates and overall survival.
Neurocognitive Effects in PCNSL Survivors
Longitudinal studies track cognitive impairment from disease and treatments using standardized neuropsychometric batteries. Interventions target rehabilitation and preventive strategies.
Why It Matters
Standardized staging and response assessment via the Lugano Classification by Cheson et al. (2014) enables consistent clinical trial comparisons and regulatory approvals for PCNSL therapies, improving patient outcomes in neurology and oncology. Rituximab combined with CHOP chemotherapy, as shown by Coiffier et al. (2002), achieves higher complete-response rates (76% versus 63% with CHOP alone) and extends overall survival in elderly diffuse large B-cell lymphoma patients, directly informing high-dose methotrexate plus rituximab regimens for PCNSL. Revised response criteria by Cheson et al. (2007) support precise evaluation of treatment efficacy in malignant lymphomas, facilitating management of PCNSL's neurological masquerade syndromes and cognitive impairments.
Reading Guide
Where to Start
"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma" by Coiffier et al. (2002), as it provides foundational evidence on rituximab's efficacy in B-cell lymphoma, directly relevant to PCNSL high-dose methotrexate-rituximab protocols.
Key Papers Explained
Coiffier et al. (2002) established rituximab's survival benefits in diffuse large B-cell lymphoma, building the basis for CNS-adapted regimens. Cheson et al. (2007) refined response criteria to enable precise trial assessments, which Cheson et al. (2014) advanced into the Lugano Classification for staging non-Hodgkin lymphomas like PCNSL. Dolecek et al. (2012) contextualizes PCNSL within CNS tumor epidemiology, linking diagnostic data to treatment needs.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research emphasizes prognostic scoring integrating genetic features with methotrexate-rituximab outcomes; recent focus lacks preprints but builds on Lugano standards for response in neurological masquerades.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in E... | 2002 | New England Journal of... | 5.5K | ✓ |
| 2 | Recommendations for Initial Evaluation, Staging, and Response ... | 2014 | Journal of Clinical On... | 5.3K | ✓ |
| 3 | Revised Response Criteria for Malignant Lymphoma | 2007 | Journal of Clinical On... | 4.4K | ✓ |
| 4 | WHO-EORTC classification for cutaneous lymphomas | 2005 | Blood | 3.8K | ✓ |
| 5 | VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA | 1964 | The Lancet | 2.7K | ✕ |
| 6 | A Clinical Evaluation of the International Lymphoma Study Grou... | 1997 | Blood | 2.5K | ✓ |
| 7 | Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Tr... | 2017 | Chemotherapy | 2.3K | ✓ |
| 8 | Chimeric antigen receptor T-cell therapy — assessment and mana... | 2017 | Nature Reviews Clinica... | 2.3K | ✓ |
| 9 | The clinical course of neuromyelitis optica (Devic’s syndrome) | 1999 | Neurology | 1.8K | ✕ |
| 10 | CBTRUS Statistical Report: Primary Brain and Central Nervous S... | 2012 | Neuro-Oncology | 1.7K | ✓ |
Frequently Asked Questions
What response criteria are used for malignant lymphoma including CNS types?
Cheson et al. (2007) revised response criteria for malignant lymphoma to standardize interpretation of clinical trials and regulatory approvals. These criteria update prior International Working Group standards, incorporating PET/CT for accurate assessment. They apply to non-Hodgkin lymphomas such as PCNSL.
How does rituximab improve outcomes in lymphoma treatment?
Coiffier et al. (2002) found that rituximab added to CHOP chemotherapy increased complete-response rates and prolonged event-free and overall survival in elderly diffuse large B-cell lymphoma patients. Toxicity did not increase significantly. This regimen informs PCNSL protocols using methotrexate and rituximab.
What is the Lugano Classification for lymphoma staging?
Cheson et al. (2014) developed the Lugano Classification to modernize evaluation, staging, and response assessment for Hodgkin and non-Hodgkin lymphomas. Recommendations emerged from a 2011 workshop at the International Conference on Malignant Lymphoma. It standardizes PCNSL diagnostic practices.
What chemotherapy regimens are relevant to CNS lymphoma?
CHOP plus rituximab, as tested by Coiffier et al. (2002), serves as a foundation for PCNSL treatments adapted with high-dose methotrexate. Single-agent pixantrone has bridged refractory diffuse large B-cell lymphoma to stem cell transplantation, per Appio et al. (2017). These address PCNSL's chemotherapy needs.
How are primary brain tumors like PCNSL statistically tracked?
Dolecek et al. (2012) reported CBTRUS statistics on primary brain and CNS tumors diagnosed in the US from 2005-2009, covering 97% population via central registries. Data include standardized inputs from healthcare sources. This informs PCNSL incidence in CNS tumor epidemiology.
What defines response in lymphoma clinical trials?
Cheson et al. (2007) defined standardized response criteria for malignant lymphoma to compare trials and approve agents. Updates address FDG-PET utility and lymphoma-specific features. Criteria support PCNSL response monitoring.
Open Research Questions
- ? How can prognostic scoring systems for PCNSL incorporate genetic features to predict rituximab and methotrexate responses?
- ? What role does intravascular lymphoma play in neurological masquerade syndromes mimicking PCNSL?
- ? How do cognitive functions in PCNSL patients change post-radiotherapy and chemotherapy?
- ? Which modifications to CHOP-rituximab regimens optimize outcomes in elderly PCNSL cases?
- ? What standardized imaging improves Lugano staging accuracy for CNS-confined lymphomas?
Recent Trends
The field comprises 23,977 works on PCNSL diagnosis and treatment, with growth data unavailable; Coiffier et al. remains highly cited (5469 citations) for rituximab-CHOP in diffuse large B-cell lymphoma, while Cheson et al. (2014) Lugano updates (5254 citations) standardize CNS lymphoma staging.
2002Research CNS Lymphoma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CNS Lymphoma Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers